This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
STERIS (STE) Dips on New Restructuring Plan, Layoff Decision
by Zacks Equity Research
STERIS (STE) aims to stop the production of the worst-hit products and move toward the existing manufacturing operations by fiscal 2020.
Veeva Systems Announces New DAM Solution for Life Sciences
by Zacks Equity Research
Veeva Vault Digital Publishing uses Veeva Systems' (VEEV) flagship Vault PromoMats or Vault MedComms platforms for updating digital content. The platform leverages on Amazon CloudFront.
Here's Why You Should Invest in Veeva Systems (VEEV) Now
by Zacks Equity Research
A solid fiscal third quarter and a plethora of recent developments make Veeva Systems (VEEV) a promising investment pick.
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Chemed's (CHE) subsidiaries continue to register strong sales.
ResMed to Buy Propeller Health, Widens Respiratory Care Suite
by Zacks Equity Research
Post the acquisition, Propeller will continue to operate as an independent entity within ResMed's (RMD) Respiratory Care suite.
Chemed Grows on Robust VITAS & Roto-Rooter Despite Headwinds
by Zacks Equity Research
Chemed's (CHE) Roto-Rooter business is showing a marked improvement on solid segmental performances at the core plumbing and drain cleaning service plus a strong uptick in water restoration.
Genomic Health (GHDX), BioCartis Extend Deal to Urology
by Zacks Equity Research
The alliance intends to develop an in vitro diagnostic (IVD) version of the Oncotype DX Genomic Prostate Score (GPS) test of Genomic Health (GHDX) on Biocartis' proprietary Idylla platform.
Here's Why You Should Invest in Accuray (ARAY) Stock Now
by Zacks Equity Research
Accuray's (ARAY) benefits from growing adoption of non-surgical treatment options among cancer patients and increasing demand for its latest offerings.
Zimmer Biomet Rides on New Operational Plan Amid Several Woes
by Zacks Equity Research
In order to tackle several near-term concerns, Zimmer Biomet (ZBH) of late begins to review its 2018 operating plan to clearly define its go-forward strategies in a number of thrust areas.
LabCorp (LH) Stock Declines 10% on Lowered 2018 Guidance
by Zacks Equity Research
Lower-than-expected volume expansion within LabCorp Diagnostics, which is also likely to persist for the rest of the year, forces LabCorp (LH) to slash its full-year guidance.
QIAGEN (QGEN) Partners NeoGenomics to Widen CDx Tests Reach
by Zacks Equity Research
The tie-up with NeoGenomics is expected to enable QIAGEN (QGEN) and pharmaceutical partners streamline the development and introduction of targeted drugs and companion diagnostics.
Here's Why You Should Invest in Omnicell (OMCL) Stock Now
by Zacks Equity Research
Omnicell (OMCL) continues to witness strong conversion wins for new XT series.
Ecolab to Buy Bioquell for Healthcare & Life Sciences' Growth
by Zacks Equity Research
Ecolab (ECL) to leverage on Bioquell's innovative bio-decontamination and isolator platforms for residue-free surface decontamination.
CVS Health Closes Aetna Deal, Focuses More on Pharmacy Wing
by Zacks Equity Research
The joint entity of CVS Health (CVS) and Aetna will provide customers with the powerful health resources of the former and the latter's network of providers for quality care.
QIAGEN's New Offerings to Broaden Hematology Testing Suite
by Zacks Equity Research
QIAGEN (QGEN) continues to progress with test menu expansion.
Here's Why You Should Invest in Surmodics (SRDX) Right Now
by Zacks Equity Research
A solid fiscal fourth quarter and lucrative IVD prospects make Surmodics (SRDX) a promising investment pick.
BD Brings HealthSight Diversion App to Combat Opioid Crisis
by Zacks Equity Research
BD's (BDX) latest development is likely to boost the company's Medication Management unit.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) continues to see impressive performance by Personal Care business. The company's focus on improving clinical quality buoys optimism.
Varian Medical's (VAR) Halcyon Gets NMPA Approval in China
by Zacks Equity Research
Varian Medical (VAR) enjoys significant international presence in radiotherapy.
Walgreens Gains from New Alliances, International Expansion
by Zacks Equity Research
Walgreens Boots (WBA) is benefiting from strategic tie-ups. The Express Scripts and Kroger deals are intended to expand its existing group purchasing efforts and product offerings.
Veeva Systems (VEEV) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems' (VEEV) impressive Q3 results can be attributed to the Subscription Service segment's solid performance. An upbeat FY19 guidance instills investor optimism in the stock
Veeva Systems (VEEV) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Veeva (VEEV) delivered earnings and revenue surprises of 18.42% and 3.93%, respectively, for the quarter ended October 2018. Do the numbers hold clues to what lies ahead for the stock?
Integra's (IART) Margin Pressure Hurts, Global Prospects High
by Zacks Equity Research
Massive gross margin declines induced by mounting costs are a major downside for Integra LifeSciences (IART).
PRA Health Launches PSN to Expand in Pediatric Care, Stock Up
by Zacks Equity Research
PRA Health's (PRAH) Center for Pediatric Clinical Development is likely to enhance pediatric clinical testing and design with the latest move.
Here's Why You Should Buy Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Thermo Fisher (TMO) gains on strength in all end markets. It witnesses consistent growth in the Asia-Pacific and emerging markets.